Technology & Innovation
Share your love
Q&A: Alexandra Miere discusses the ACTOR and HERMES studies | Ophthalmology Times
Photo of Alexandra Miere at the 2025 EURETINA meeting in Paris Alexandra Miere discusses retinal studies published in EURETINA journal. The first, the ACTOR study, explores vascular remodeling in neovascular AMD patients treated with ranibizumab. The second, the HERMES study,…
Q&A: Harvey Uy on the power of digital images and records | Ophthalmology Times
Photo of Harvey Uy, MD, DPBO, FVRSP, at the 2025 EURETINA meeting Harvey Uy, MD, DPBO, FVRDP, a retina specialist from the Peregrine Eye and Laser Institute in the Philippines, discussed the transformative power of digital image management in ophthalmology.…
Q&A: Prem S. Subramanian, MD, PhD, on neuro-ophthalmic insights at EyeCon 2025 | Ophthalmology Times
Prem S. Subramanian, MD, PhD, emphasized the importance of pattern recognition in distinguishing ocular from neurologic causes of visual symptoms during EyeCon 2025. (Image credit: AdobeStock/ryandi) “Pattern recognition is key,” emphasized Prem S. Subramanian, MD, PhD, as he discussed the…
Q&A: Boris Stanzel on the use of methotrexate in PVR cases | Ophthalmology Times
Photo of Boris Stanzel, MD, at the 2025 EURETINA meeting Professor Boris Stanzel, MD, presented research on methotrexate’s use in PVR retinal detachment surgery at the 2025 EURETINA congress, which was held in Paris, France. The study of 20 patients…
Conavi Medical submits Novasight Hybrid IVUS/OCT System to FDA for 510(k) clearance | Ophthalmology Times
(Image Credit: AdobeStock/gguy) Conavi Medical has submitted its Novasight Hybrid™ IVUS/OCT intravascular imaging system to the US Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. While optical coherence tomography (OCT) is traditionally used to monitor retinal diseases,…
Justis P. Ehlers, MD, on the HELIOS trial for NPDR | Ophthalmology Times
Note: Captions are generated with the assistance of AI. Justis Ehlers, MD, spoke with Ophthalmology Times to share key findings from his recent presentation at the 2025 Retina Society meeting, which was held in Chicago, Illinois. Ehlers shared data from…
Optos and Toku to incorporate BioAge AI into existing retinal imaging devices | Ophthalmology Times
(Image credit: AdobeStock/hakule) Optos and Toku have reached an agreement to make Toku’s BioAge available to users of Optos Daytona, Monaco, MonacoPro, and California devices in the United States. The companies state that by incorporating the AI solution, BioAge, eye…
Q&A: Andreas Pollreisz explains when to use and not use widefield OCT-A imaging | Ophthalmology Times
Photo of Andreas Pollreisz at the 2025 EURETINA meeting in Paris, France Andreas Pollreisz, MD, a medical and surgical retina specialist from the Medical University of Vienna, discussed widefield OCT-A imaging at the 2025 EURETINA meeting in Paris, France. He…
Using OCT-A to explore biomarkers for neurodegenerative diseases
Amir H. Kashani, MD, PhD, a professor of ophthalmology at Johns Hopkins University, discussed a significant research publication in Alzheimers and Dementia that explored OCT-A angiography’s potential in studying neurodegenerative diseases. The study focused on developing a consensus method for…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…